Chronic Lung Diseases
74,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
37 °P sammeln
  • Broschiertes Buch

Chronic lung diseases: pathophysiology and therapeutics provides a much-needed reference tool for pathologists, practicing pulmonologists and researchers who are currently working on lung related diseases. Each chapter addresses a specific lung disease, which it introduces before turning to the disease's pathophysiology, current treatment and future prospects. Various key lung diseases are covered, including chronic obstructive pulmonary disease, lung cancer, tuberculosis, chronic pneumonia, acute respiratory distress syndrome, asthma, cystic fibrosis and pulmonary hypertension. Medical…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Chronic lung diseases: pathophysiology and therapeutics provides a much-needed reference tool for pathologists, practicing pulmonologists and researchers who are currently working on lung related diseases. Each chapter addresses a specific lung disease, which it introduces before turning to the disease's pathophysiology, current treatment and future prospects.
Various key lung diseases are covered, including chronic obstructive pulmonary disease, lung cancer, tuberculosis, chronic pneumonia, acute respiratory distress syndrome, asthma, cystic fibrosis and pulmonary hypertension. Medical students and researchers whose work involves pulmonary related disorders will find this work both instructive and informative.
Autorenporträt
Sheikh Rayees is a pharmacologist working at the University of Illinois at Chicago, USA. He completed his MSc. In Biotechnology at HNB Garhwal University (a Central University) followed by his doctoral degree at the prestigious CSIR-Indian Institute of Integrative Medicine and SMVDU, Jammu, India. Mr. Rayees is currently working towards understanding the biology and therapeutics of respiratory disorders like acute lung injury, acute respiratory distress syndrome etc. He has published several articles in leading peer-reviewed journals and has sound academic credentials. Mr. Rayees received several awards throughout his doctoral and postdoctoral research career.   Inshah Din is a research scholar working at Govt. Medical College, Srinagar. She completed her M.Sc. in Clinical Biochemistry, followed by an M.Phil. and Ph.D. in Biochemistry at the University of Kashmir. She has worked as a Junior Research fellow at the prestigious Sher-i-Kashmir Institute of Medical Sciences, Srinagar.  Ms. Din has sound academic credentials, and has published several research articles in peer-reviewed journals.  Fayaz Malik is an Indian cancer biologist and pharmacologist at the prestigious CSIR-Indian Institute of Integrative Medicine. He is known for his studies on investigating the regulatory mechanisms of cancer stem cells during tumor metastasis. He has also studied the identification of signaling networks that confer resistance to current anti-cancer therapies. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the most coveted Indian science awards, for his contributions to the Biosciences in 2014. In addition, the Department of Science and Technology of the Government of India awarded him the Swaranajayanti Fellowship, one of the most prestigious Fellowship awards, for his advanced researchin cancer biology. Gurdarshan Singh is a pharmacologist working as a principal scientist at the prestigious CSIR-Indian Institute of Integrative Medicine. He completed his M.Sc., M.Phil. and Ph.D. at Jammu University, India. Mr. Gurdarshan is currently Head of the PK-PD Toxicology Division at the CSIR-Indian Institute of Integrative Medicine, Jammu. His main research interests include evaluating new and potent drug-like molecules for their safety pharmacology, pharmacodynamic and pharmacokinetic properties. He has worked in several areas of pre-clinical research, e.g. asthma, hypertension and cancer. Dr. Singh holds several patents and contributed to the development of Risorine, an anti-tuberculosis drug and the world's first boosted-rifampicin treatment with a fixed-dose combination.